These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21249164)

  • 1. α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.
    Toyohara J; Hashimoto K
    Open Med Chem J; 2010 May; 4():37-56. PubMed ID: 21249164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
    Ishikawa M; Hashimoto K
    Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
    Hashimoto K
    Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain.
    Ni R; Marutle A; Nordberg A
    J Alzheimers Dis; 2013; 33(3):841-51. PubMed ID: 23042213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease.
    Shen J; Wu J
    Int Rev Neurobiol; 2015; 124():275-92. PubMed ID: 26472533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
    Sadigh-Eteghad S; Talebi M; Mahmoudi J; Babri S; Shanehbandi D
    Neuroscience; 2015 Jul; 298():81-93. PubMed ID: 25881725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of new therapeutic drugs based on the pathophysiology of schizophrenia].
    Hashimoto K
    Seishin Shinkeigaku Zasshi; 2011; 113(4):368-73. PubMed ID: 21702128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease.
    Lilja AM; Porras O; Storelli E; Nordberg A; Marutle A
    J Alzheimers Dis; 2011; 23(2):335-47. PubMed ID: 21116052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
    Faghih R; Gfesser GA; Gopalakrishnan M
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease.
    Ma KG; Qian YH
    Neuropeptides; 2019 Feb; 73():96-106. PubMed ID: 30579679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
    Kroker KS; Moreth J; Kussmaul L; Rast G; Rosenbrock H
    Brain Res Bull; 2013 Jul; 96():28-38. PubMed ID: 23639920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The α7 nAChR selective agonists as drug candidates for Alzheimer's disease.
    Fan H; Gu R; Wei D
    Adv Exp Med Biol; 2015; 827():353-65. PubMed ID: 25387975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
    Beinat C; Banister SD; Herrera M; Law V; Kassiou M
    CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.
    Leiser SC; Bowlby MR; Comery TA; Dunlop J
    Pharmacol Ther; 2009 Jun; 122(3):302-11. PubMed ID: 19351547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.
    Nordberg A
    Biol Psychiatry; 2001 Feb; 49(3):200-10. PubMed ID: 11230871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current agonists and positive allosteric modulators of
    Yang T; Xiao T; Sun Q; Wang K
    Acta Pharm Sin B; 2017 Nov; 7(6):611-622. PubMed ID: 29159020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease.
    Hernandez CM; Kayed R; Zheng H; Sweatt JD; Dineley KT
    J Neurosci; 2010 Feb; 30(7):2442-53. PubMed ID: 20164328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.
    Stoiljkovic M; Kelley C; Nagy D; Leventhal L; Hajós M
    Neuropharmacology; 2016 Nov; 110(Pt A):102-108. PubMed ID: 27422408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activators of α7 nAChR as Potential Therapeutics for Cognitive Impairment.
    Wang X; Bell IM; Uslaner JM
    Curr Top Behav Neurosci; 2020; 45():209-245. PubMed ID: 32451955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.